Comparison of mini-simple limbal epithelial transplantation and conjunctival-limbal autograft for the treatment of primary pterygium: a randomised controlled trial

Br J Ophthalmol. 2023 Nov 22;107(12):1776-1781. doi: 10.1136/bjo-2021-320707.

Abstract

Purpose: The purpose of this double-masked, parallel randomised controlled trial was to compare the recurrence rate and other outcomes between conjunctival-limbal autograft (CLAu) and mini-simple limbal epithelial transplantation (mini-SLET) after excision of pterygium.

Methods: Eligibility criteria for participants was the presence of a primary nasal pterygium extending equally to or greater than two millimetres on the cornea on its horizontal axis from the nasal limbus. The participants were allocated into two groups (CLAu and mini-SLET) using simple randomisation with a table of random numbers. Participants and the outcome assessor were masked to the intervention. The study protocol is listed and available on https://clinicaltrials.gov (Identifier: NCT03363282).

Results: A total of 61 eyes were enrolled in the study, 33 underwent CLAu (group 1) and 28 mini-SLET (group 2), all eyes were analysed in each group. At 2, 3, 6 and 12 months the CLAu group exhibited a recurrence of 0%, 6.1%, 8.1% and 8.1%, while the mini-SLET exhibited a recurrence of 0%, 17.9%, 50% and 53.5% (p<0.05). There were no intraoperative or postoperative complications in either of the two groups.

Conclusion: The findings of this study suggest that mini-SLET has a higher recurrence rate and provides no advantage over CLAu in the treatment of primary pterygium.

Keywords: conjunctiva; cornea; ocular surface; treatment surgery; wound healing.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Autografts
  • Conjunctiva / transplantation
  • Follow-Up Studies
  • Humans
  • Limbus Corneae* / surgery
  • Pterygium* / surgery
  • Recurrence
  • Transplantation, Autologous
  • Treatment Outcome

Supplementary concepts

  • Pterygium Of Conjunctiva And Cornea

Associated data

  • ClinicalTrials.gov/NCT03363282